Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhysioGenix Inc.

This article was originally published in Start Up

Executive Summary

PhysioGenix wants to reduce drug failure rates in clinical trials with multigenic rat models that can be used in parallel for target validation, drug screening, and predictive toxicology. The company is providing animal models and services related to therapeutic proof-of-concept and predictive toxicology to help pharma clients accelerate their product development processes. Over time, PhysioGenix expects to provide these services in concert with internal early drug development programs.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC090892

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel